MED vs. LMNR, CSV, BYND, CBUS, SENEA, YSG, LWAY, DJCO, TPB, and CVGW
Should you be buying Medifast stock or one of its competitors? The main competitors of Medifast include Limoneira (LMNR), Carriage Services (CSV), Beyond Meat (BYND), Cibus (CBUS), Seneca Foods (SENEA), Yatsen (YSG), Lifeway Foods (LWAY), Daily Journal (DJCO), Turning Point Brands (TPB), and Calavo Growers (CVGW). These companies are all part of the "consumer staples" sector.
Medifast (NYSE:MED) and Limoneira (NASDAQ:LMNR) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Medifast has a net margin of 9.27% compared to Limoneira's net margin of -5.40%. Medifast's return on equity of 56.06% beat Limoneira's return on equity.
Medifast has higher revenue and earnings than Limoneira. Limoneira is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.
Medifast received 94 more outperform votes than Limoneira when rated by MarketBeat users. Likewise, 64.05% of users gave Medifast an outperform vote while only 62.42% of users gave Limoneira an outperform vote.
In the previous week, Medifast had 1 more articles in the media than Limoneira. MarketBeat recorded 2 mentions for Medifast and 1 mentions for Limoneira. Limoneira's average media sentiment score of 0.05 beat Medifast's score of 0.00 indicating that Limoneira is being referred to more favorably in the news media.
Medifast has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Limoneira has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
95.5% of Medifast shares are owned by institutional investors. Comparatively, 64.4% of Limoneira shares are owned by institutional investors. 2.1% of Medifast shares are owned by insiders. Comparatively, 9.0% of Limoneira shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Medifast presently has a consensus price target of $61.00, indicating a potential upside of 80.96%. Limoneira has a consensus price target of $23.00, indicating a potential upside of 15.87%. Given Medifast's higher possible upside, research analysts clearly believe Medifast is more favorable than Limoneira.
Summary
Medifast beats Limoneira on 13 of the 18 factors compared between the two stocks.
Get Medifast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medifast Competitors List
Related Companies and Tools
